Medpace Holdings, Inc. (NASDAQ:MEDP) Shares Sold by Wellington Management Group LLP

Wellington Management Group LLP decreased its holdings in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 90.6% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 39,135 shares of the company's stock after selling 376,120 shares during the period. Wellington Management Group LLP owned approximately 0.13% of Medpace worth $13,002,000 at the end of the most recent quarter.

Several other hedge funds have also made changes to their positions in the business. Lindbrook Capital LLC boosted its stake in shares of Medpace by 27.6% during the fourth quarter. Lindbrook Capital LLC now owns 134 shares of the company's stock worth $45,000 after buying an additional 29 shares during the period. HBK Sorce Advisory LLC raised its holdings in Medpace by 0.5% during the fourth quarter. HBK Sorce Advisory LLC now owns 5,384 shares of the company's stock worth $1,789,000 after purchasing an additional 29 shares in the last quarter. Assetmark Inc. raised its holdings in Medpace by 20.1% during the fourth quarter. Assetmark Inc. now owns 173 shares of the company's stock worth $57,000 after purchasing an additional 29 shares in the last quarter. Proficio Capital Partners LLC raised its holdings in Medpace by 4.1% during the fourth quarter. Proficio Capital Partners LLC now owns 730 shares of the company's stock worth $243,000 after purchasing an additional 29 shares in the last quarter. Finally, Schulhoff & Co. Inc. raised its holdings in Medpace by 1.2% during the fourth quarter. Schulhoff & Co. Inc. now owns 2,630 shares of the company's stock worth $874,000 after purchasing an additional 30 shares in the last quarter. Institutional investors and hedge funds own 77.98% of the company's stock.

Medpace Price Performance

Medpace stock traded up $2.92 during mid-day trading on Friday, reaching $296.50. The company had a trading volume of 421,400 shares, compared to its average volume of 358,753. Medpace Holdings, Inc. has a 1 year low of $250.05 and a 1 year high of $459.77. The company has a market capitalization of $8.52 billion, a P/E ratio of 23.48, a P/E/G ratio of 3.81 and a beta of 1.55. The stock's 50-day simple moving average is $298.09 and its 200-day simple moving average is $324.07.

Medpace (NASDAQ:MEDP - Get Free Report) last issued its earnings results on Monday, April 21st. The company reported $3.67 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.06 by $0.61. Medpace had a net margin of 19.17% and a return on equity of 51.48%. The company had revenue of $558.57 million during the quarter, compared to analysts' expectations of $528.38 million. During the same period last year, the company posted $3.20 earnings per share. On average, equities analysts forecast that Medpace Holdings, Inc. will post 12.29 EPS for the current fiscal year.

Insider Transactions at Medpace

In other news, Director Fred B. Davenport, Jr. sold 1,712 shares of the firm's stock in a transaction that occurred on Thursday, April 24th. The shares were sold at an average price of $301.82, for a total transaction of $516,715.84. Following the completion of the transaction, the director now directly owns 2,998 shares of the company's stock, valued at $904,856.36. This trade represents a 36.35% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Corporate insiders own 20.30% of the company's stock.

Analyst Upgrades and Downgrades

MEDP has been the subject of several analyst reports. Mizuho cut their price target on shares of Medpace from $400.00 to $355.00 and set an "outperform" rating for the company in a report on Wednesday, April 9th. Leerink Partners initiated coverage on shares of Medpace in a report on Monday, March 24th. They set a "market perform" rating and a $330.00 price target for the company. William Blair reissued a "market perform" rating on shares of Medpace in a report on Tuesday, April 22nd. Robert W. Baird cut their price target on shares of Medpace from $340.00 to $313.00 and set a "neutral" rating for the company in a report on Wednesday, April 23rd. Finally, Truist Financial cut their price target on shares of Medpace from $333.00 to $300.00 and set a "hold" rating for the company in a report on Wednesday, April 23rd. Eleven research analysts have rated the stock with a hold rating and three have given a buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Hold" and an average price target of $349.30.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.